Literature DB >> 9129047

Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients.

A Ahlin1, G Elinder, J Palmblad.   

Abstract

Interferon-gamma (IFN-gamma) is recommended as prophylaxis against infections in patients with chronic granulomatous disease (CGD). However, since the optimal dose, the dosing interval, and the mechanisms of action are not well-defined, we studied the effects on CGD neutrophil (PMN) functions ex vivo of interferon-gamma (IFN-gamma). Evaluations were made on oxidative capacity, measured by superoxide anion production and chemiluminescence after stimulation with f-met-leu-phe (f-MLP) or phorbol-myristate-acetate, the killing of Aspergillus fumigatus hyphae (assessed as conversion of the tetrazolium salt MTT to formazan), and on the expression of Fc gammaRI receptor (CD64). After randomization, 9 CGD patients (4 with gp91phox, 3 with p47phox, 1 with p67phox deficiency and 1 with unspecified CGD) were given IFN-gamma, either 50 or 100 microg/m2 subcutaneously on 2 consecutive days after double blinded randomization. Furthermore, one female hyperlyonized X-linked carrier with a CGD phenotype was also studied separately after IFN-gamma treatment. Evaluations were made the day before and on days 1, 3, 8, and 18 after IFN-gamma administration. The killing of A fumigatus hyphae, being close to zero before IFN-gamma, was enhanced on day 3, being 36% higher than pretreatment values in the high-dose CGD group and 17% in the low-dose group. The expression of Fc gammaRI on PMN increased 3.7-fold in the high-dose and 2.3-fold in the low-dose CGD group, being maximal on day 1. Oxidative functions were raised in only selected patients represented by different subtypes of CGD. The hyperlyonized carrier of X-linked CGD responded to IFN-gamma with more enhanced oxidative responses and Aspergillus killing of her PMNs than the other patients. This study suggests that a higher dose of IFN-gamma than currently recommended confers transient enhancements of certain PMN functions in CGD patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129047

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils.

Authors:  A Ahlin; G Lärfars; G Elinder; J Palmblad; H Gyllenhammar
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 3.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 4.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

5.  Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis.

Authors:  Stacy J Park; Molly A Hughes; Marie Burdick; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

6.  Immunization enhances inflammation and tissue destruction in response to Porphyromonas gingivalis.

Authors:  Cataldo W Leone; Haneen Bokhadhoor; David Kuo; Tesfahun Desta; Julia Yang; Michelle F Siqueira; Salomon Amar; Dana T Graves
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

7.  Type III interferon is a critical regulator of innate antifungal immunity.

Authors:  Vanessa Espinosa; Orchi Dutta; Constance McElrath; Peicheng Du; Yun-Juan Chang; Bryan Cicciarelli; Amy Pitler; Ian Whitehead; Joshua J Obar; Joan E Durbin; Sergei V Kotenko; Amariliz Rivera
Journal:  Sci Immunol       Date:  2017-10-06

Review 8.  Chronic granulomatous disease and other disorders of neutrophil function.

Authors:  N R Kamani; A J Infante
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 10.817

9.  INF-γ Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself.

Authors:  Michael A Ellison; Gail Thurman; Christy M Gearheart; Ryan H Seewald; Christopher C Porter; Daniel R Ambruso
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

10.  In vitro interferon γ improves the oxidative burst activity of neutrophils in patients with chronic granulomatous disease with a subtype of gp91phox deficiency.

Authors:  Serkan Filiz; Dilara F Kocacik Uygun; Sadi Köksoy; Emel Şahin; Olcay Yeğin
Journal:  Cent Eur J Immunol       Date:  2015-04-22       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.